SIHUAN PHARM (00460) rose nearly 4%, up 3.94% to HK$1.32 by the time of writing, with a turnover of HK$12.825 million. Recently, the company announced that six new specifications of the polylactic acid facial filler (commonly known as the "Youthful Needle"), independently developed by its subsidiary Mei Yan Space Biotechnology (Jilin) Co., Ltd., have been officially approved by China's National Medical Products Administration. This marks another significant advancement following the product's initial approval, further enhancing the company's market positioning in the field of regenerative aesthetic products. Prior to this specification expansion, the product was already approved in three specifications: 45mg/bottle, 75mg/bottle, and 150mg/bottle, catering to different needs such as preventative management, combination therapy, and comprehensive rejuvenation. The newly approved specifications—60mg/bottle, 80mg/bottle, 100mg/bottle, 110mg/bottle, 120mg/bottle, and 130mg/bottle—will further enrich the product selection spectrum.